Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial

<br><strong>Background: </strong>Cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection continue to rise in the Arabian Peninsula 7 years after it was first described in Saudi Arabia. MERS-CoV poses a significant risk to public health security because of an abse...

ver descrição completa

Detalhes bibliográficos
Principais autores:	Folegatti, PM, Bittaye, M, Flaxman, A, Lopez, FR, Bellamy, D, Kupke, A, Mair, C, Makinson, R, Sheridan, J, Rohde, C, Halwe, S, Jeong, Y, Park, Y-S, Kim, J-O, Song, M, Boyd, A, Tran, N, Silman, D, Poulton, I, Datoo, M, Marshal, J, Themistocleous, Y, Lawrie, A, Roberts, R, Berrie, E, Becker, S, Lambe, T, Hill, A, Ewer, K, Gilbert, S
Formato:	Journal article
Idioma:	English
Publicado em:	Elsevier 2020

Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial

Registros relacionados